Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D.T. PACE Versus High Dose Melphalan and Autologous Transplant in Multiple Myeloma
NCT00083876Phase 3Completed
- Sponsor
- University of Arkansas
- Start
- Sep 1998
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of thalidomide in multiple myeloma (MM) (2 arms), sponsored by University of Arkansas. Primary endpoint: Equivalence or superiority of D.T. PACE to tandem transplant. Started Sep 1998; status: completed.
02
Drugs
thalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00083876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00083876.